Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12

Beverly E. Sha, Michelle Onorato, John A. Bartlett, Ronald J. Bosch, Evgenia Aga, Mostafa Nokta, Elizabeth M. Adams, Xiao Dong Li, John Eldridge, Richard B Pollard

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

We examined the safety and immunogenicity of a human leukocyte antigen-based HIV envelope polyvalent synthetic peptide vaccine, C4-V3, alone and in combination with subcutaneous IL-12 in nine HIV-infected patients. Lymphocyte proliferative responses increased threefold or more to all four peptides at two consecutive post-immunization timepoints for four individuals. Three responders had received IL-12, suggesting a possible adjuvant effect of IL-12. Transient mild injection site reactions (7/9) and systemic symptoms (3/9) occurred.

Original languageEnglish (US)
Pages (from-to)1203-1206
Number of pages4
JournalAIDS
Volume18
Issue number8
DOIs
StatePublished - May 21 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12'. Together they form a unique fingerprint.

  • Cite this

    Sha, B. E., Onorato, M., Bartlett, J. A., Bosch, R. J., Aga, E., Nokta, M., Adams, E. M., Li, X. D., Eldridge, J., & Pollard, R. B. (2004). Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS, 18(8), 1203-1206. https://doi.org/10.1097/00002030-200405210-00015